Company intelligence / Profile preview

Pharmiva AB (publ)

Lund, Sweden

Ownership: Private
Employees: ~5
Development stage: Commercial

Overview

Pharmiva developed Vernivia, a CE-marked, antibiotic-free vaginal mousse based on its proprietary Venerol platform. Vernivia has been launched commercially in Sweden as an over-the-counter treatment for bacterial vaginosis. The company holds patents on its delivery technology and plans to expand into additional women’s health indications such as yeast infections and STD prevention. Clinical results support efficacy in treating bacterial vaginosis without antibiotics.

Therapeutic areas: Women's HealthInfectious Diseases
Modalities: Topical medical device/moussenon-antibiotic therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Vernivia

Commercial

Indications: Bacterial vaginosis

Beyond the preview

Go deeper on Pharmiva AB (publ).

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmiva AB (publ).

Explore the full profile